Commonwealth Equity Services’s Pyxis Oncology PYXS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$50.7K Sell
34,755
-5,000
-13% -$7.54K ﹤0.01% 4200
2025
Q4
$45.7K Sell
39,755
-21,400
-35% -$75.5K ﹤0.01% 4189
2025
Q3
$136K Hold
61,155
﹤0.01% 4034
2025
Q2
$67K Buy
61,155
+17,905
+41% +$20.2K ﹤0.01% 4128
2025
Q1
$42K Buy
43,250
+17,000
+65% +$22.7K ﹤0.01% 4084
2024
Q4
$41K Buy
26,250
+10,000
+62% +$28.8K ﹤0.01% 3998
2024
Q3
$60K Hold
16,250
﹤0.01% 3914
2024
Q2
$54K Sell
16,250
-14,000
-46% -$58.9K ﹤0.01% 3886
2024
Q1
$129K Buy
30,250
+17,300
+134% +$72.8K ﹤0.01% 3755
2023
Q4
$23K Hold
12,950
﹤0.01% 3810
2023
Q3
$26K Buy
+12,950
New +$30K ﹤0.01% 3715

Other funds holding PYXS

Commonwealth Equity Services's PYXS Position: Q1 2026 in Review

Commonwealth Equity Services reduced its Pyxis Oncology (PYXS) stake by 13% in Q1 2026, selling an estimated $7.54K and leaving 34,755 shares worth $50.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4200.

Commonwealth Equity Services first reported a position in PYXS in Q3 2023 and has held it in 11 quarters since. The position peaked at $136K in Q3 2025. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • Commonwealth Equity Services held 34,755 shares of Pyxis Oncology worth $50.7K as of Q1 2026.
  • Commonwealth Equity Services sold 5,000 Pyxis Oncology shares in Q1 2026, an estimated $7.54K.
  • Pyxis Oncology made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q1 2026, its #4200 holding.
  • Commonwealth Equity Services first reported a position in Pyxis Oncology in Q3 2023 and has held it in 11 quarters since.
  • Commonwealth Equity Services's Pyxis Oncology position peaked at $136K in Q3 2025.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Commonwealth Equity Services's 13F filing for Q1 2026, filed 27 Apr 2026.